image description

Press Releases

Press Releases

December 4, 2018
Revance Announces China Market License Agreement with Fosun Pharma for RT002
– Upfront payment of $30 million , plus potential milestone payment and tiered royalties on future sales – NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and
November 20, 2018
Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 20, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor
November 7, 2018
Revance to Participate in the Credit Suisse Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 7, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare
November 1, 2018
Revance Releases Third Quarter 2018 Results
- Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation
October 11, 2018
Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
NEWARK, Calif. --(BUSINESS WIRE)--Oct. 11, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C.
September 20, 2018
Revance Receives Great Place to Work Certification

NEWARK, Calif. --(BUSINESS WIRE)--Sep. 20, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company was certified as a great workplace this month by the independent

Displaying 21 - 30 of 173